Rochester NY, 16 February 17, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare and haircare solutions, proudly welcomes to the company Dr. Carla Mazzeo PhD, a global authority in exosome research who has more than 30 publications. She will spearhead company advancements in exosome-based skin, scalp, and hair care. Dr. Mazzeo, a leader in exosome research since 2004, was a Director and Senior Scientific Researcher at Boston University and Boston University Medical Center. She brings unparalleled expertise to enhance RESILIÉLLE’s commitment to excellence. [Read more…]
RESILIÉLLE COSMETICS LLC Unveils Exosome Results of First-Ever 100-Person Trial on Age Zero Exosome Cosmetic Serum Applied Topically Post Microneedling
Eight Medical Spas Participate in Nationwide Pioneering Study
Rochester NY, February 13, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare solutions, proudly announces the successful completion of the world’s first 100-person microneedling-plus-exosome trial, conducted at eight renowned medspas across the country. The clinicians participated in the trial in order to analyze what is the most effective amount of RESILIÉLLE Age Zero ExosomeTM topical serum to be applied after facial microneedling. [Read more…]
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
Nano-race: Industrial Landscape of Exosome-Based Therapeutics and Diagnostics
Exosomes are nano-sized vesicles ranging from 30-200nm that are present in eukaryotic fluids and facilitate a diverse range of cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
Because of their far ranging potential, exosomes can be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Today, a surging number of companies are developing exosome-based products and technologies.
Exosome Market Competitors
Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.
[Read more…]
dG Medical Group Launches Regenerative Medicine Program using Mesenchymal Stem Cell Exosomes
Clearwater, FL, September 13, 2023 – dG Medical Group, with a dedication to providing patients, physicians, and clinicians the most advanced and beneficial technology, is launching research studies in the use of Mesenchymal Stem Cell (MSC) Exosomes for a variety of medical conditions. This landmark of an achievement makes it the only product legally permitted to be sold for clinical use through research. [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 27
- Next Page »